Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.01% | 80.30% | 106.09% | 47.73% | 32.14% |
| Total Depreciation and Amortization | -5.60% | 19.84% | 26.62% | 22.22% | -14.97% |
| Total Amortization of Deferred Charges | 23.44% | 0.00% | -23.43% | -22.44% | -35.11% |
| Total Other Non-Cash Items | 11,847.37% | 176.59% | 7,940.00% | -95.66% | -100.70% |
| Change in Net Operating Assets | -138.65% | -247.70% | 163.60% | -67.72% | 375.15% |
| Cash from Operations | 19.81% | 55.55% | 135.01% | 20.59% | 57.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.08% | -3.07% | 228.24% | 136.82% | 4.39% |
| Cash from Investing | -91.01% | -2.51% | 225.64% | 136.82% | 3.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | -- | -- | 66.94% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,714.42% | 100.00% | -321,328.57% | -100.24% | -10,300.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.75% | 2,754.03% | 79.43% | -105.09% | 2,279.91% |